RecruitingPhase 1NCT07005713

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants

A Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple- Ascending Doses of BGB-16673 in Patients With Chronic Spontaneous Urticaria and in Healthy Participants

Sponsor

BeOne Medicines

Enrollment

58 participants

Start Date

Jul 19, 2025

Study Type

INTERVENTIONAL

Conditions

Chronic Spontaneous Urticaria

Summary

This is a Phase 1b study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of multiple-ascending doses of tacabrutideg in adults with chronic spontaneous urticaria (CSU) and in healthy participants.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Tacabrutideg for people with chronic spontaneous urticaria. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTacabrutideg

Administered orally

DRUGPlacebo

Administered orally

Locations(9)

Peking University Third Hospital

Beijing, Beijing Municipality, China

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

Dermatology Hospital of Southern Medical University

Guangzhou, Guangdong, China

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Xiangya Hospital of Central South University

Changsha, Hunan, China

The Affiliated Hospital of Qingdao University Branch West Coast

Qingdao, Shandong, China

Chengdu Second Peoples Hospital

Chengdu, Sichuan, China

Hangzhou First Peoples Hospital

Hangzhou, Zhejiang, China

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07005713

Related Trials

A Trial of HRS-3095 in Healthy Volunteers

NCT07686484

Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)

NCT07642557

Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.

NCT07402213

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)

NCT0771790510 locations

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

NCT0721961569 locations